Search Result

Results for "

orally efficacious

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (5) Apoptosis (2) Bacterial (2) Beta-secretase (1) Biochemical Assay Reagents (1) Btk (2) CDK (1) Chemerin Receptor (2) Cholinesterase (ChE) (1) Drug Derivative (1) Environmental Pollutants (1) ERK (1) Estrogen Receptor/ERR (2) Factor Xa (6) IFNAR (1) Integrin (2) Interleukin Related (6) IRAK (1) Isotope-Labeled Compounds (4) JAK (1) LDLR (1) MAP4K (1) MAPKAPK2 (MK2) (2) MCHR1 (GPR24) (1) MEK (1) Mineralocorticoid Receptor (1) Monoamine Oxidase (1) Opioid Receptor (1) p38 MAPK (2) PAI-1 (1) Parasite (5) Progesterone Receptor (1) PROTACs (2) Raf (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) ROS Kinase (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (10) Infection (9) Inflammation/Immunology (19) Metabolic Disease (10) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15253

Tiplaxtinin Maximum Cited Publications 15 Publications Verification PAI-039; Tiplasinin	PAI-1 Apoptosis	Metabolic Disease Cancer
Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC₅₀ of 2.7 μM .

HY-N1428C

Ferric citrate 5 Publications Verification Iron(III) citrate; Zerenex	Reactive Oxygen Species (ROS) Antibiotic	Metabolic Disease
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-153321

Bexobrutideg 1 Publications Verification NX-5948; BTK-IN-24	PROTACs Btk	Inflammation/Immunology Cancer
Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker) .

HY-10268

Betrixaban 5 Publications Verification PRT054021	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-15200

Agerafenib 5+ Cited Publications CEP-32496; RXDX-105	Raf	Cancer
Agerafenib (CEP-32496; RXDX-105) is a highly potent and orally efficacious inhibitor of BRAF ^V600E with a K_d of 14 nM.

HY-112542

Nemadectin CL-287088; LL-F28249 α	Parasite Antibiotic	Infection
Nemadectin (CL-287088), an orally active broad-spectrum endectocide, is highly efficacious against natural infections of all the major canine gastrointestinal helminthes. Anthelmintic activity .

HY-12445

Asnuciclib 2 Publications Verification CDKI-73; LS-007	CDK Apoptosis	Inflammation/Immunology Cancer
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .

HY-107427

PF-3644022 2 Publications Verification	MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC₅₀s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .

HY-141692

IL-17 modulator 4	Interleukin Related	Inflammation/Immunology Cancer
IL-17 modulator 4 is a proagent of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome .

HY-16911

AFN-1252 10+ Cited Publications API-1252; Debio 1452	Bacterial Antibiotic	Infection
AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC₉₀ values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-10596

BMS-688521 1 Publications Verification	Integrin	Inflammation/Immunology
BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC₅₀ of 2.5 nM in the adhesion assay and an IC₅₀ of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for Tyk2 JH2 and an IC₅₀ value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-10268A

Betrixaban maleate 5 Publications Verification PRT054021 maleate	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban maleate shows antithrombotic effect .

HY-47030

Ferric citrate hydrate	Environmental Pollutants Biochemical Assay Reagents	Metabolic Disease
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-121212

Icosabutate	LDLR	Metabolic Disease Inflammation/Immunology
Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .

HY-14390

LAS101057 1 Publications Verification	Adenosine Receptor	Inflammation/Immunology
LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist.

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-15199

Agerafenib hydrochloride CEP-32496 hydrochloride; RXDX-105 hydrochloride	Raf	Cancer
Agerafenib hydrochloride is a highly potent and orally efficacious inhibitor of BRAF ^V600E with a K_d of 14 nM.

HY-A0287S

Clomiphene-d5 hydrochloride Clomifene-d₅ hydrochloride; (Z/E)-Enclomiphene-d₅ hydrochloride; (Z/E)-Enclomifene-d₅ hydrochloride	Isotope-Labeled Compounds Estrogen Receptor/ERR	Metabolic Disease Cancer
Clomifene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene)-d₅ hydrochloride is a deuterium labeled Clomifene hydrochloride (HY-A0287A). Clomiphene hydrochloride is an orally active ovulation-inducing agent. Clomiphene hydrochloride binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene hydrochloride can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene hydrochloride ameliorates memory impairment in PCOS models. Clomiphene hydrochloride mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene hydrochloride can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer .

HY-10268S

Betrixaban-d6 PRT054021-d₆	Factor Xa	Cardiovascular Disease
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor .

HY-10268B

Betrixaban hydrochloride PRT054021 hydrochloride	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .

HY-102036

G-744	Btk	Inflammation/Immunology
G-744 is a highly potent, selective and orally active Btk inhibitor with an IC₅₀ of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis .

HY-10268R

Betrixaban (Standard) PRT054021 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease
Betrixaban (Standard) is the analytical standard of Betrixaban. This product is intended for research and analytical applications. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-12738

PF-3882845	Mineralocorticoid Receptor Progesterone Receptor	Cardiovascular Disease Metabolic Disease
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC₅₀=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC₅₀ of 310 nM .

HY-147642

ChemR23-IN-4	Chemerin Receptor	Inflammation/Immunology
ChemR23-IN-4 (Compound 13) is a potent and orally efficacious ChemR23 inhibitor with an IC₅₀ of 17 nM against human ChemR23 .

HY-111368

EBI-1051	MEK	Cancer
EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC₅₀ of 3.9 nM.

HY-145352

ChemR23-IN-2	Chemerin Receptor	Inflammation/Immunology
ChemR23-IN-2 is a potent and orally efficacious ChemR23 inhibitor with an IC₅₀ value of 3.2 nM.

HY-A0287A

Clomiphene hydrochloride Clomifene hydrochloride; (Z/E)-Enclomiphene hydrochloride; (Z/E)-Enclomifene hydrochloride	Estrogen Receptor/ERR	Metabolic Disease Cancer
Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) hydrochloride is an orally active ovulation-inducing agent. Clomiphene hydrochloride binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene hydrochloride can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene hydrochloride ameliorates memory impairment in PCOS models. Clomiphene hydrochloride mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene hydrochloride can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer .

HY-128354

CWHM-1552	Parasite	Infection
CWHM-1552 is an orally efficacious inhibitor of P. falciparum with IC₅₀s of 51 nM and 53 nM for 3D7 and Dd2 strain, respectively .

HY-B0477A

Quinapril CI-906 free acid	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models .

HY-141692B

(R)-IL-17 modulator 4	Interleukin Related	Inflammation/Immunology
(R)-IL-17 modulator 4 is the R-configure of IL-17 modulator 4 (HY-141692). IL-17 modulator 4 is a proagent of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome .

HY-141535A

IL-17 modulator 1 disodium	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-141535

IL-17 modulator 1	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-118709

Ro 23-7637	Drug Derivative	Metabolic Disease
Ro 23-7637 is an orally active, efficacious antiobesity agent .

HY-115721

Antimalarial agent 2	Parasite	Infection
Antimalarial agent 2 is a novel orally efficacious antimalarials that suggests a fast in vitro killing profile.

HY-122078

FR-190809	Acyltransferase	Metabolic Disease
FR-190809 is a potent, nonadrenotoxic, orally efficacious acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor, with an IC₅₀ of 45 nM .

HY-145704

Antimalarial agent 8	Parasite	Infection
Antimalarial agent 8 (Compound 7e) is a novel orally active class of antimalarials. Antimalarial agent 8 is potent in vitro against P. falciparum and is orally efficacious (40 mg/kg) in an in vivo mouse model of malaria .

HY-120608

BMS-814580	MCHR1 (GPR24)	Metabolic Disease
BMS-814580 is an orally active, highly efficacious MCHR1 inhibitor with a K_i of 16.9 nM against hMCHR1. BMS-814580 shows antiobesity activities .

HY-112542R

Nemadectin (Standard) CL-287088 (Standard); LL-F28249 α (Standard)	Reference Standards Parasite Antibiotic	Infection
Nemadectin (Standard) is the analytical standard of Nemadectin. This product is intended for research and analytical applications. Nemadectin (CL-287088), an orally active broad-spectrum endectocide, is highly efficacious against natural infections of all the major canine gastrointestinal helminthes. Anthelmintic activity .

HY-10268S1

Betrixaban-d4 PRT054021-dsub>4	Isotope-Labeled Compounds Factor Xa	Cardiovascular Disease
Betrixaban-d₄ (PRT054021-d₄) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-115987

MAO-B-IN-6	Monoamine Oxidase	Neurological Disease
MAO-B-IN-6 is a potent, selective and orally active MAO-B inhibitor with an IC₅₀ of 0.019 µM. MAO-B-IN-6 shows more efficacious than Safinamide in vitro and in vivo. MAO-B-IN-6 has the potential for the research of parkinson's disease (PD) .

HY-11051

JNJ-20788560	Opioid Receptor	Inflammation/Immunology
JNJ-20788560 is a selective and orally active delta opioid receptor agonist with an affinity of 2.0 nM for DOR (rat brain cortex binding assay). JNJ-20788560 also is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. JNJ-20788560 can be used for the research of the relief of inflammatory hyperalgesia .

HY-B0477AS2

Quinapril-d4 CI-906-d₄	Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Quinapril-d₄ (CI-906-d₄) is deuterium labeled Quinapril. Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models .

HY-141692A

IL-17 modulator 4 sulfate	Interleukin Related	Inflammation/Immunology
IL-17 modulator 4 sulfate is a proagent of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 sulfate is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome .

HY-146399

AChE/BChE-IN-9	Cholinesterase (ChE) ROS Kinase	Neurological Disease
AChE/BChE-IN-9 (Compound 7a) is a potent, orally active AChE and BChE inhibitor with IC₅₀ values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. AChE/BChE-IN-9 is also an efficacious antioxidant with an IC₅₀ of 57.35 μM. AChE/BChE-IN-9 is able to chelate iron and modulates aggregation of amyloid β_{1-42. AChE-IN-16 can cross the BBB} .

HY-128774

AM-6494	Beta-secretase	Neurological Disease
AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC₅₀=0.4 nM) with in vivo selectivity over BACE2 (IC₅₀=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-114622

AFN-1252 tosylate API-1252 tosylate; Debio 1452 tosylate	Bacterial Antibiotic	Infection
AFN-1252 (API-1252) tosylate is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 tosylate exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 tosylate exhibits typical MIC₉₀ values of 0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 tosylate is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-175547

PROTAC HPK1 Degrader-5	PROTACs MAP4K ERK Interleukin Related IFNAR	Inflammation/Immunology Cancer
PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader (DC50 = 5.0 nM; Dmax ≥ 99%). PROTAC HPK1 Degrader-5 significantly inhibits SLP76 phosphorylation and enhanced ERK pathway activation through degrading HPK1, thereby stimulating IL-2 and IFN-γ release. PROTAC HPK1 Degrader-5 exhibits the ability to overcome the immunosuppressive effects imposed by PGE2, NECA or TGF-β. PROTAC HPK1 Degrader-5 alone efficaciously inhibits tumor growth in an MC38 syngeneic mouse model. PROTAC HPK1 Degrader-5 can be used for the study of tumor (such as colorectal cancer) immunotherapy (Pink: Target protein ligand (HY-175549); Blue: E3 ligand (HY-W023573); Black: Linker; E3 ligand + Linker (HY-175551)) .

HY-10268S2

Betrixaban-13C6 PRT054021-¹³C₆	Isotope-Labeled Compounds	Cardiovascular Disease
Betrixaban- ¹³C₆ (PRT054021- ¹³C₆) is ¹³C labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-107427R

PF-3644022 (Standard)	Reference Standards MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
PF-3644022 (Standard) is the analytical standard of PF-3644022 (HY-107427). This product is intended for research and analytical applications. PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC₅₀ of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated K_inase (PRAK) with IC₅₀s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-112542

Nemadectin CL-287088; LL-F28249 α	Infection Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-parasitic Disease Research Disease Research Fields Source Classification	Parasite Antibiotic
Nemadectin (CL-287088), an orally active broad-spectrum endectocide, is highly efficacious against natural infections of all the major canine gastrointestinal helminthes. Anthelmintic activity .

HY-112542R

Nemadectin (Standard) CL-287088 (Standard); LL-F28249 α (Standard)	Microorganisms Macrolide Antibiotics Antibiotics Anti-parasitic Disease Research Source Classification	Reference Standards Parasite Antibiotic
Nemadectin (Standard) is the analytical standard of Nemadectin. This product is intended for research and analytical applications. Nemadectin (CL-287088), an orally active broad-spectrum endectocide, is highly efficacious against natural infections of all the major canine gastrointestinal helminthes. Anthelmintic activity .

Cat. No.	Product Name	Chemical Structure

HY-A0287S

Clomiphene-d5 hydrochloride

Clomifene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene)-d₅ hydrochloride is a deuterium labeled Clomifene hydrochloride (HY-A0287A). Clomiphene hydrochloride is an orally active ovulation-inducing agent. Clomiphene hydrochloride binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene hydrochloride can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene hydrochloride ameliorates memory impairment in PCOS models. Clomiphene hydrochloride mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene hydrochloride can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer .

HY-10268S

Betrixaban-d6
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor .

HY-10268S1

Betrixaban-d4
Betrixaban-d₄ (PRT054021-d₄) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-B0477AS2

Quinapril-d4

Quinapril-d₄ (CI-906-d₄) is deuterium labeled Quinapril. Quinapril is a potent, orally active, non-peptide and nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE). Quinapril specifically interrupts the conversion of angiotensin I to angiotensin II in both plasma and tissue. Quinapril is enzymatically hydrolyzed to a pharmacologically active diacid form quinaprilat. Quinapril is efficacious in hypertensive models .